Soluble adhesion molecule E-selectin predicts cardiovascular events in Japanese patients with type 2 diabetes mellitus

Matsumoto, Kazunari; Fujishima, Keiichiro; Moriuchi, Akira; Saishoji, Hiroe; Ueki, Yukitaka

doi:10.1016/j.metabol.2009.06.011

Cited by 16 publications

(15 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prospective data in patients with diabetes are limited: sE‐selectin levels measured from postprandial blood samples were significantly related to 6‐year incident cardiovascular disease in 392 Japanese patients with Type 2 diabetes [10]. Our work confirms these findings in higher‐risk Caucasian patients and extends this work by showing that this relationship is present for both coronary heart disease and cardiovascular disease events.…”

Section: Discussionsupporting

confidence: 76%

Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type 2 diabetes1

Natarajan

Marshall

Kesteven³

et al. 2011

Diabetic Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 76%

Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type 2 diabetes1

Natarajan

Marshall

Kesteven³

et al. 2011

Diabetic Medicine

View full text Add to dashboard Cite

show abstract

“…However, previous studies reported that sE-selectin concentrations were significantly increased in T2DM patients with CVDs compared with T2DM patients without CVDs. 13,14 The high level of sE-selectin observed in both diabetic groups compared with controls may be due to endothelial activation and inflammation in response to hyperglycemia; this activation and inflammation may occur regardless the presence or absence of CVDs. 15 In 2014, Sandoval-Pinto et al 16 evaluated serum levels of sE-selectin in 283 patients with acute coronary syndrome (ACS) and compared them with levels in 205 healthy subjects.…”

Section: Discussionmentioning

confidence: 99%

Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications

et al. 2019

View full text Add to dashboard Cite

Objective Type 2 diabetes mellitus (T2DM) is a main risk factor for development of cardiovascular diseases (CVDs) and endothelial dysfunction. This study aimed to investigate serum levels of soluble vascular cell adhesion molecule 1 (sVCAM-1), intercellular adhesion molecule 1 (sICAM-1), and endothelium selectin (sE-selectin) in T2DM patients with macrovascular complications. Methods A cross-sectional study of 21 controls, 30 T2DM patients without CVDs, and 30 T2DM patients with CVDs was conducted. Serum levels of soluble adhesion molecules including sVCAM-1, sICAM-1, and sE-selectin were determined using ELISA. Results Serum levels of sVCAM-1, sICAM-1, and sE-selectin were higher in T2DM patients than in controls. Levels of serum sVCAM-1 were higher in T2DM patients with CVDs compared with T2DM patients without CVDs. In T2DM patients with CVDs, significant positive associations were observed between sVCAM-1, sICAM-1, and sE-selectin levels (r = 0.575, p = 0.001 and r = 0.378, p = 0.040). Conclusions Circulating levels of soluble adhesion molecules were elevated in T2DM patients, regardless of whether the patients had cardiovascular complications. Only sVCAM-1 was considered a useful marker for the prediction of CVDs in T2DM patients.

show abstract

“…We could not find any difference in adhesion molecule levels according to the history of CVD. Circulating E-selectin was found to be associated with the severity of coronary artery disease in sporadic crosssectional analyses 15 , and to predict cardiovascular events in patients with type 2 diabetes mellitus 16 , but in other studies performed so far in patients with overt CVD, no clear-cut association emerged. [17][18][19][20][21][22] E-selectin was not associated with carotid atherosclerosis in a recent study in ESRD patients, 23 and did not predict adverse outcome in such patients.…”

Section: Discussionmentioning

confidence: 94%

P‐selectin, E‐selectin, and CD40L over time in chronic hemodialysis patients

Bossola¹,

Rosa²,

Tazza³

et al. 2011

Hemodialysis International

View full text Add to dashboard Cite

The aim of this study was to measure P-selectin, E-selectin, and CD-4L levels over time in chronic hemodialysis (HD) patients. Thirty stable patients with end-stage renal failure undergoing chronic HD were included in the study. Blood samples were obtained before HD for measurement of P-selectin, E-selectin, and CD-40L. Measurements were performed at month 0 (T0), 3 (T2), 8 (T3), and 13 (T4). The levels of P-selectin, E-selectin, and CD40L were also analyzed according to the occurrence of cardiovascular disease (CVD) and to CVD-related mortality. The levels of CD40L and P-selectin changed significantly over time, decreasing at month 3 and 6 and returning at the T0 levels at month 13. Conversely, E-selectin levels did not. The levels of CD40L, P-selectin and E-selectin over time did not differ significantly between patients with age ≤ 65 or > 65 years, between patients with or without CVD, or between patients who died or who survived during the follow-up. In end-stage renal failure patients undergoing chronic HD, CD40L and P-selectin, but not E-selectin, showed a transient decrease over time, and the serum levels of these molecules were not associated with CVD or with CVD-related mortality.

show abstract

Soluble adhesion molecule E-selectin predicts cardiovascular events in Japanese patients with type 2 diabetes mellitus

Cited by 16 publications

References 30 publications

Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type 2 diabetes1

Impact of biomarkers for endothelial dysfunction and procoagulant state on 10-year cardiovascular risk in Type 2 diabetes1

Levels of soluble cell adhesion molecules in type 2 diabetes mellitus patients with macrovascular complications

P‐selectin, E‐selectin, and CD40L over time in chronic hemodialysis patients

Contact Info

Product

Resources

About